<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="brief-report"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Endocrinol (Lausanne)</journal-id><journal-id journal-id-type="iso-abbrev">Front Endocrinol (Lausanne)</journal-id><journal-id journal-id-type="publisher-id">Front. Endocrinol.</journal-id><journal-title-group><journal-title>Frontiers in Endocrinology</journal-title></journal-title-group><issn pub-type="epub">1664-2392</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC12098035</article-id><article-id pub-id-type="doi">10.3389/fendo.2025.1499565</article-id><article-categories><subj-group subj-group-type="heading"><subject>Endocrinology</subject><subj-group><subject>Perspective</subject></subj-group></subj-group></article-categories><title-group><article-title>Associated factors and principal pathophysiological mechanisms of type 2 diabetes mellitus</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Luyao</given-names></name><uri xlink:href="https://loop.frontiersin.org/people/2353250/overview"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Lianxin</given-names></name><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Jiaxin</given-names></name><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Sheng</surname><given-names>Changting</given-names></name><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Maoyi</given-names></name><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Hu</surname><given-names>Zhipeng</given-names></name><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/716572/overview"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Yue</surname><given-names>Rensong</given-names></name><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib></contrib-group><aff id="aff1">
<institution>Department of Endocrinology, Hospital of Chengdu, University of Traditional Chinese Medicine</institution>, <addr-line>Chengdu</addr-line>, <country>China</country>
</aff><author-notes><fn fn-type="edited-by"><p>Edited by: Guy A. Rutter, Imperial College London, United Kingdom</p></fn><fn fn-type="edited-by"><p>Reviewed by: Maria Bayliak, Vasyl Stefanyk Precarpathian National University, Ukraine</p></fn><corresp id="fn001">*Correspondence: Zhipeng Hu, <email xlink:href="mailto:2574922786@qq.com">2574922786@qq.com</email>; Rensong Yue, <email xlink:href="mailto:songrenyue@cdutcm.edu.cn">songrenyue@cdutcm.edu.cn</email>
</corresp></author-notes><pub-date pub-type="epub"><day>09</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>16</volume><elocation-id>1499565</elocation-id><history><date date-type="received"><day>21</day><month>9</month><year>2024</year></date><date date-type="accepted"><day>11</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2025 Wang, Li, Liu, Sheng, Yang, Hu and Yue</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Wang, Li, Liu, Sheng, Yang, Hu and Yue</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>Type 2 diabetes mellitus(T2DM) as a common chronic disease with an increasing prevalence worldwide that poses a great threat to individual health, and is characterized by chronic hyperglycemia resulting from insulin resistance (IR) coupled with &#x003b2;-cell dysfunction. Mitochondrial dysfunction, obesity, gut microbiota, oxidative stress and inflammation have emerged as a significant contributor to the etiology of T2DM, affecting various metabolic processes critical for glucose homeostasis. This short review underscores their role in enhancing T2DM-related molecular mechanisms and explores recent advancements in diabetic management, further highlights the importance of personalized care plans to address the complexities of the T2DM and aims to improve patient quality of life and long-term health outcome.</p></abstract><kwd-group><kwd>type 2 diabetes mellitus</kwd><kwd>pathogenic mechanism</kwd><kwd>insulin resistance</kwd><kwd>mitochondrial function</kwd><kwd>obesity</kwd><kwd>gut microbiota</kwd></kwd-group><funding-group><funding-statement>The author(s) declare that financial support was received for the research and/or publication of this article. This work was supported by Natural Science Foundation of Sichuan province (No. 23NSFC6268), Science and Technology Planning Project of sichuan province (No. 2023YFS0329), National Natural Science Foundation of China (No.82305209).</funding-statement></funding-group><counts><fig-count count="2"/><table-count count="0"/><equation-count count="0"/><ref-count count="78"/><page-count count="7"/><word-count count="2861"/></counts><custom-meta-group><custom-meta><meta-name>section-in-acceptance</meta-name><meta-value>Diabetes: Molecular Mechanisms</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><label>1</label><title>Introduction</title><p>Type 2 diabetes mellitus (T2DM) is a renowned overgrowing endocrine metabolic disease, and occurs as a result of insulin resistance (IR) and inadequate insulin production, resulting in hyperglycemia, presenting a substantial burden on global healthcare systems (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>). IR is characterized by an impaired cellular response to insulin stimulation in peripheral tissues, such as the liver, skeletal muscle and adipose tissue.</p><p>As T2DM advances, progressive beta cell dysfunction occurs, results in relative insulin deficiency of insulin secretion (<xref rid="B3" ref-type="bibr">3</xref>). Besides that, mitochondrial dysfunction, obesity, gut microbiota, oxidative stress and inflammation are also implicated in the etiology of T2DM,these different pathogenic factors underscore the urgent need for multifactorial approach that address not only control of hyperglycemia but also the broader implications and side-effects impact of overall health and well-being (<xref rid="B4" ref-type="bibr">4</xref>). T2DM management, pharmacological interventions alone is insufficient, lifestyle modifications, weight management, regular physical activity and patient self-management are critical to advance diabetic care (<xref rid="B5" ref-type="bibr">5</xref>). In fact, by addressing multifactorial characteristics of onset and development in T2DM, a focus on individualized care and prevent the risk of complications must consider patient-specific needs, effective and sustainable treatment preferences, comorbidities, ultimately optimizing patient overall quality of life and long-term health outcomes (<xref rid="B6" ref-type="bibr">6</xref>). Lastly, we discuss the latest therapeutic innovations, like gene therapy, regenerative medicine and identification of omics-related biomarkers, aid in gaining a deeper comprehension of holistic care and precision medicine among diabetic patients.</p></sec><sec id="s2"><label>2</label><title>Mechanisms and pathogenic factors of IR</title><sec id="s2_1"><label>2.1</label><title>Mitochondrial dysfunction</title><p>Mitochondria, commonly known as the &#x0201c;powerhouses&#x0201d; of cells, containing their own double-stranded DNA (mtDNA), which encodes 13 polypeptides constitute mostly part of the electron transfer chain (ETC) (<xref rid="B7" ref-type="bibr">7</xref>). In fact, the mitochondrial ETC is the site of oxidative phosphorylation (OXPHOS), which is key in glucose metabolism and the biggest net producer of ATP in mammalian cells (<xref rid="B8" ref-type="bibr">8</xref>). Mitochondria play a crucial role in apoptosis, signaling, oxidation processes, and cellular energy consumption and balance, as well as are vital for the proper functioning and survival of pancreatic &#x003b2;-cells (<xref rid="B9" ref-type="bibr">9</xref>). When mitochondria are dysfunctional, uncontrolled fission or fusion occurs, like impaired mitochondrial fusion or excessive mitochondrial fission, resulting in impaired mitochondrial dynamics and mitochondrial fragmentation. Reactive oxygen species (ROS) are next to the location of the mtDNA and produced by OXPHOS, this makes the mtDNA highly susceptible to oxidative damage, thus increasing the probability of mutations and further disturbing mitochondrial energy metabolism (<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B11" ref-type="bibr">11</xref>). Meanwhile, this oxidative damage compromises mETC function and worsens energy failure, in addition to oxidative stress and dysfunctional mitochondria, which have been implicated in the part pathogenesis of various diseases, including DM (<xref rid="B12" ref-type="bibr">12</xref>). Peroxisome proliferator-activated receptors (PPARs) agonists, like pioglitazone is a promising thiazolidinediones and restores mitochondrial function in patients with T2DM (<xref rid="B13" ref-type="bibr">13</xref>). Glimins represent a new class of oral glucose-lowering drugs, primarily targeting the mitochondrial respiratory chain complex to reduce the production of ROS and prevent mitochondrial meability transition pore opening, thereby restoring mitochondrial function in skeletal muscle, liver, and pancreas of diabetic patients (<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B15" ref-type="bibr">15</xref>).</p></sec><sec id="s2_2"><label>2.2</label><title>Mitochondrial biogenesis</title><p>Mitochondrial biogenesis is implicated in cells grow and mitochondrial responses to environmental cues and metabolic demands, which is a key feature of mitochondrial function, its dysregulation contributes to the development and progression of T2DM (<xref rid="B16" ref-type="bibr">16</xref>). Transcriptional coactivators peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1&#x003b1;), initiates mitochondrial biogenesis pathway by sequential activations of nuclear transcription factors, including nuclear respiratory factors (NRF1/2), estrogen-related receptor-alpha(ERR-&#x003b1;), followed by mitochondrial transcription factor A (TFAM) and mtDNA replication and transcription. Dysregulation of PGC-1&#x003b1; activity leads to impaired mitochondrial biogenesis and gene expression in oxidative phosphorylation and metabolic disorders (<xref rid="B17" ref-type="bibr">17</xref>). Sirtuin 1 (Sirt1) is a nicotinamide adenine dinucleotide (NAD+) -dependent histone deacetylase that plays a significant role in modulating PGC-1&#x003b1; activity, promoting mitochondrial biogenesis and renewal (<xref rid="B18" ref-type="bibr">18</xref>). Inflammatory cytokines, calcium (Ca<sup>2+</sup>) regulation and metabolic stressors, such as hyperglycaemia and dyslipidaemia, are also linked to inhibit mitochondrial biogenesis and promote onset of IR (<xref rid="B19" ref-type="bibr">19</xref>). Substances such as 5-Aminoimidazole-4-carboxamide ribotide, GW501516, and various natural compounds present in epicatechin, have been identified as potential pharmacological via stress kinases, transcription factors and peroxisome proliferator-activated receptors (PPARs) activation, as well as mitochondrial function restoration to alleviate metabolic abnormalities (<xref rid="B20" ref-type="bibr">20</xref>). Besides, mitochondrial gene therapy has emerged as an innovative tool hold significant promise for restoring mitochondrial function and enhancing cellular bioenergetics (<xref rid="B21" ref-type="bibr">21</xref>). Addressing mitochondrial dysfunction and T2DM crosstalk is crucial for understanding the biochemistry mechanisms involved in overproduction of ROS, reduced ATP synthesis, dysregulated mitochondrial dynamics, poor mitochondrial biogenesis, and impaired mitochondrial gene expression, resulting in imbalance between energy generation and consumption, further exacerbate metabolic disorders, which may be exactly identified the relationship between mitochondrial dysfunction and molecular mechanisms underlying T2DM is multifaceted and complex (<xref rid="B16" ref-type="bibr">16</xref>)(<xref rid="f1" ref-type="fig">
<bold>Figures&#x000a0;1a, b</bold>
</xref>).</p><fig position="float" id="f1"><label>Figure&#x000a0;1</label><caption><p>
<bold>(a)</bold> illustrates mitochondrial dysfunction (abnormal mitochondrial fusion or excessive mitochondrial fission) triggers mitochondrial fragmentation, anomalous mitophagy, overproduced ROS, reduced ATP synthesis, dysregulated mitochondrial dynamics, further impairs cellular metabolism and contributes to T2DM progression; <bold>(b)</bold> presents the extracellular environment cues affect mitochondrial biogenesis and dynamics, as dysfunctional mitochondria fail to adapt to changing metabolic demands, leading to cellular dysfunction and T2DM; <bold>(c)</bold> presents adipocyte-induced obesity is significant in T2DM pathogenesis, and obesity-related dyslipidemia, inflammation and insistent hyperglycemia condition regulate IR through different molecular pathway.</p></caption><graphic xlink:href="fendo-16-1499565-g001" position="float"/></fig></sec><sec id="s2_3"><label>2.3</label><title>Obesity</title><p>An long-term imbalance in energy between intake and expenditure is a key characteristic of individuals with obesity, and then chronic exposure to hyperglycemia, dyslipidemia, glucotoxicity impairs &#x003b2;-cell function and viability, leading to progressive deterioration of insulin secretion capacity (<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B23" ref-type="bibr">23</xref>). Brown adipose tissue (BAT) is a distinct type of adipose tissue that dissipates energy and plays a natural anti-obesity role. White adipose tissue (WAT) primarily stores energy. Disturbances in BAT and WAT homeostasis have been associated with certain microbial imbalances and onset of obesity (<xref rid="B24" ref-type="bibr">24</xref>). Given that obesity has been closely implicated in the pathogenesis of T2DM (<xref rid="f1" ref-type="fig">
<bold>Figure&#x000a0;1c</bold>
</xref>). Browning agents, such as cold exposure, &#x003b2;-3 adrenergic receptor agonists (CL 316243, BRL 26830A), short-chain fatty acids (butyrate, propionate, acetate), are compounds that can promote the conversion of WAT into BAT, may hold promise as a target for treating and preventing T2DM (<xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B26" ref-type="bibr">26</xref>). Besides, as reciprocal causation between obesity and T2DM, significant progress in the pharmacological treatment revolve around insulin resistance-mediated obesity. Metformin is the preferred first line antidiabetic drug, exerts its therapeutic effects by increasing insulin sensitivity, glucose uptake by activating adenosine monophosphate activated protein kinase, promoting weight loss, improving lipid profiles, as well as modulating mitochondrial dynamics and biogenesis, thus contributing to its metabolic benefits in T2DM onset (<xref rid="B27" ref-type="bibr">27</xref>). Sodium-glucose cotransporter 2 (SGLT2) inhibitors, such as dapagliffozin and empagliffozin, have emerged as promising therapeutic agents for antihyperglycemic management (<xref rid="B28" ref-type="bibr">28</xref>). These substances reduce body weight, initially through a direct effect, and subsequently by shifting substrate utilization from carbohydrates to lipids, thereby reducing body fat, including visceral and subcutaneous fat (<xref rid="B29" ref-type="bibr">29</xref>, <xref rid="B30" ref-type="bibr">30</xref>). Gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) are secreted by cells in the human gut after food intake and regulate insulin release by pancreatic &#x003b2;-cells, and involved in blood sugar homeostasis. Tirzepatide acts on the GIPR/GLP-1R receptors, and is a recently developed drug useful in the treatment of T2DM and for weight loss, studies show its role in improving circulating levels of adiponectin, eventually influences lipid and glucose metabolism (<xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B32" ref-type="bibr">32</xref>). What needs to be emphasized that each drug has specific mechanisms and potential side effects, necessitating the significance of personalized treatment plan. Besides that, bariatric surgery like sleeve gastrectomy, one-anastomosis gastric bypass, and Roux-en-Y gastric bypass have the potential to induce remission of T2DM-related obesity (<xref rid="B33" ref-type="bibr">33</xref>).</p></sec><sec id="s2_4"><label>2.4</label><title>Gut microbiota</title><p>The human gut microbiome is a complex ecosystem, composed of bacteria, archaea, fungi, viruses and protozoa in the human intestinal tract, which participate in material and energy metabolism, each exerting a unique influence on host metabolism (<xref rid="B34" ref-type="bibr">34</xref>, <xref rid="B35" ref-type="bibr">35</xref>). In the context of T2DM, the gut microbiome exhibits notable changes, termed dysbiosis, which is closely related with dysregulation of a host metabolism, where there is an increase in bacteria that negatively impact metabolic health and a decrease in beneficial bacteria (<xref rid="B36" ref-type="bibr">36</xref>, <xref rid="B37" ref-type="bibr">37</xref>). Bacteroides uniformis and Bacteroides acidifaciens can negatively improve glucose tolerance and insulin sensitivity, and are instrumental in managing T2DM, Faecalibacterium, Akkermansia, and Roseburia also exhibit similar negative correlations with the metabolic diseases (<xref rid="B38" ref-type="bibr">38</xref>, <xref rid="B39" ref-type="bibr">39</xref>). Therefore, diabetic patients often exhibit an increase in harmful bacteria, such as Escherichia and Prevotella, Iatcu OC (<xref rid="B40" ref-type="bibr">40</xref>). Short-chain amino acids (SCFAs),like butyrate, propionate and acetate regulate pancreatic beta-cell activity, reduce hepatic gluconeogenesis, and modulate immune system functions (<xref rid="B41" ref-type="bibr">41</xref>). Moreover, the alternation of branched-chain amino acids (BCAAs) increases liver gluconeogenesis and inhibits liver adipogenesis, directly contributes to the pathogenesis of T2DM (<xref rid="B42" ref-type="bibr">42</xref>, <xref rid="B43" ref-type="bibr">43</xref>). Notably, the changes in gut microbiota are related to LPS-induced inflammatory responses, exacerbating IR in T2DM,further emphasizing microbiome&#x02019;s role in glucose homeostasis and immune response (<xref rid="B44" ref-type="bibr">44</xref>) (<xref rid="f2" ref-type="fig">
<bold>Figure&#x000a0;2a</bold>
</xref>). This emerging field offers diverse applications, particularly in modifying the gut environment through the administration of probiotics, including Bifidobacterium (adolescentis, animalis, bifidum, reuteri, breve, longum)and Lactobacillus (acidophilus, casei, fermentum, gasseri, johnsonii, paracasei, plantarum, rhamnosus, and salivarius) can potentially alleviate or even reverse the metabolic dysfunctions associated with T2DM (<xref rid="B45" ref-type="bibr">45</xref>). Additionally, diabetic medications Alpha-glucosidase inhibitors promote the growth of beneficial microbes such as Bacteroides, Lactobacillus, and Faecalibacterium, while reducing populations of potentially pathogenic bacteria like Ruminococcus and Butyricicoccus (<xref rid="B46" ref-type="bibr">46</xref>). GLP-1 agonists also promote the growth of SCFA-producing bacteria such as Bifidobacterium and Bacteroides, further supporting glycemic control and metabolic health (<xref rid="B47" ref-type="bibr">47</xref>). Sodium-glucose co-transporter type 2 inhibitors, such as sotagliflozin, impact the gut microbiome by decreasing the Firmicutes/Bacteroides ratio and enhancing fatty acid production (<xref rid="B48" ref-type="bibr">48</xref>). Spermidine can significantly change the composition and function of intestinal microbiota, moderately reduce the level of circulating LPS, improve metabolic endotoxemia, weaken cell apoptosis to enhance intestinal barrier function (<xref rid="B49" ref-type="bibr">49</xref>). Fecal microbiota transplantation (FMT) effectively mitigates damage to the intestinal barrier through altering the microbial structure (<xref rid="B50" ref-type="bibr">50</xref>).</p><fig position="float" id="f2"><label>Figure&#x000a0;2</label><caption><p>
<bold>(a)</bold> illustrates dysbiosis of gut microbiota is related to LPS-induced inflammatory pathways, as well as BCAAs, SCFAs and BAs disrupt metabolic pathways, eventually triggers IR by impairing the gut mucosal barrier and increasing intestinal permeability; <bold>(b)</bold> presents inflammatory pathways impacting IR and possible action, and illustrates chronic hyperglycemia, oxidative stress, lipid metabolism and B-cell dysfunction can activate pro-inflammatory pathways, further exacerbate IR in T2DM; <bold>(c)</bold> presents oxidative stress-induced insulin resistance-related signaling pathways, and summarizes the mitochondrial dysfunction, lipid oxidation, insulin signaling pathway, inflammatory response, as well as its related pathways are instrumental in regulating T2DM.</p></caption><graphic xlink:href="fendo-16-1499565-g002" position="float"/></fig></sec><sec id="s2_5"><label>2.5</label><title>Inflammation</title><p>T2DM patients have elevated blood glucose and free fatty acids levels, dyslipidemia, impaired insulin receptor function. Metabolic inflammation is one of markedly causatives among the metabolic derangement factors (<xref rid="B51" ref-type="bibr">51</xref>). Specifically, chronic hyperglycemia and hyperlipidemia are the typical features of diabetes manifestations, which inevitably lead to glucolipotoxicity and in turn alter mitochondrial function. Dysfunctional mitochondria induce non-physiological generation of ROS, exacerbate the disturbance of inflammatory microenvironmental balance between adipose and pancreatic islet tissue, inevitably forming a vicious cycle (<xref rid="B52" ref-type="bibr">52</xref>, <xref rid="B53" ref-type="bibr">53</xref>). Along with chronic production of proinflammatory cytokines and inefficient fatty acid &#x003b2;-oxidation, triggering a decrease in &#x003b2; cell insulin secretion and an increase in IR. Chronic overload of free fatty acids and glucose trigger inflammatory pathways (AMPK and PPAR&#x003b3;) directly or via increased production of ROS, which is the possible causative factor in the metabolic inflammation (<xref rid="B54" ref-type="bibr">54</xref>, <xref rid="B55" ref-type="bibr">55</xref>),depicted in <xref rid="f2" ref-type="fig">
<bold>Figure&#x000a0;2b</bold>
</xref>. Adipose tissue-derived cytokines, such as tumor necrosis factor-alpha (TNF-&#x003b1;) and interleukin-6 (IL-6), promote IR by interfering with insulin signaling pathway and promoting inflammation (<xref rid="B56" ref-type="bibr">56</xref>). The anti-inflammatory mediators, such as visfatin, plasminogen activator inhibitor-1, blocking IL-1R,anti-IL-1&#x003b2;,anti-TNF-&#x003b1;,CCR2 antagonists and IL-6R inhibitors, have emerged as available therapeutic approach for reversing T2DM (<xref rid="B57" ref-type="bibr">57</xref>).</p></sec><sec id="s2_6"><label>2.6</label><title>Oxidative stress</title><p>Reactive oxygen species(ROS) are byproducts of mitochondrial metabolism, as hyperglycemia advances, oxidative stress in &#x003b2;-cells is often driven by mitochondrial ROS, which overwhelms the body&#x02019;s antioxidant defenses, leading to impairment of insulin signaling pathway and metabolic dysregulation, thus plays a significant role in the pathophysiology of T2DM and its associated complications causing IR (<xref rid="B58" ref-type="bibr">58</xref>, <xref rid="B59" ref-type="bibr">59</xref>). Most antioxidants, like SS-31 (elamipretide) and SkQ1,that reduces oxidative stress and maintains mitochondrial function offer a potential treatment strategy for T2DM and its complications (<xref rid="B60" ref-type="bibr">60</xref>). Additionally, ROS-mediated oxidative stress activates stress kinases and pro-inflammatory pathways, such as nuclear factor &#x003ba;B (NF-&#x003ba;B),which stimulates the release of proinflammatory cytokines and further exacerbating &#x003b2;-cell dysfunction and IR (<xref rid="B1" ref-type="bibr">1</xref>) (<xref rid="f2" ref-type="fig">
<bold>Figure&#x000a0;2c</bold>
</xref>). Quercetin, curcumin, resveratrol, vitamin C and vitamin D have emerged as critical mediators in this antioxidant process, linking nuclear factor erythroid 2-related factor 2 (Nrf2) pathway and inflammation signaling to counteract &#x003b2;-cell dysfunction in diabetes (<xref rid="B61" ref-type="bibr">61</xref>). Glutathione (GSH), a water-soluble antioxidant, plays a critical role in maintaining cellular homeostasis and mitigating oxidative stress, study shows that metformin, teneligliptin, and pioglitazone not only impacts GSH redox pathway but also preserves &#x003b2;-cell function (<xref rid="B62" ref-type="bibr">62</xref>, <xref rid="B63" ref-type="bibr">63</xref>). Therapeutic strategies focusing on reducing oxidative stress, enhancing antioxidant defenses, and focusing on Mediterranean diet, such as vegetables, function and preventing diabetes progression (<xref rid="B64" ref-type="bibr">64</xref>). It becomes increasingly evident that therapeutic strategies focusing on targeting oxidative stress pathways and enhancing antioxidant defenses as promising therapeutic strategies to preserve &#x003b2;-cell function and prevent diabetic progression.</p></sec></sec><sec sec-type="conclusions" id="s3"><label>3</label><title>Conclusion and perspective</title><p>Type 2 diabetes mellitus stands as the most prevalent metabolic disease globally, characterized by intricate pathophysiological mechanism, including IR, impaired glucose homeostasis and &#x003b2;-cell dysfunction, genetic and environmental variables are also implicated in the etiology of T2DM. Considering multifactorial contributors of diabetes, such as mitochondrial dysfunction, obesity and gut microbiota, mutually reinforcing each other, and creating a vicious cycle that exacerbates both insulin sensitivity and resistance, underscores the urgent need for effective T2DM management strategies that not only offer improved hypoglycemic control but also address the broader health implications (<xref rid="B5" ref-type="bibr">5</xref>). Retatrutide is a novel triple agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1 and glucagon receptors, distinguishes itself for its favorable glycemic control ability and its broader effects such as increasing insulin secretion, improving glucose homeostasis, and refining appetite modulation, clinical trials have demonstrated significant reductions in body weight superior to dulaglutide, tirzepatide, and even semaglutide (<xref rid="B65" ref-type="bibr">65</xref>&#x02013;<xref rid="B67" ref-type="bibr">67</xref>). Dorzagliatin and Cadisegliatin are promising antidiabetic drugs activate Glucokinase (GK), which regulate glucose metabolism and enhance beta cell function in diabetic patients, although they are still in the clinical stages (<xref rid="B68" ref-type="bibr">68</xref>, <xref rid="B69" ref-type="bibr">69</xref>).</p><p>As diabetes management continues to advance, regenerative medicine has evolved significantly, with modern therapeutic avenues and a broader focus on immunomodulatory properties and adjuvant delivery biomaterials to repair damaged tissues, like mesenchymal stem cells (<xref rid="B70" ref-type="bibr">70</xref>). Immune cell-derived exosomes (including engineered exosomes) may also regulate the function of immune cells by transferring miRNA and mRNA, making them a promising directions reverse metabolic disorders of T2DM (<xref rid="B71" ref-type="bibr">71</xref>). Although they have great clinical application prospects, there are associated hurdles about immune rejection, tumorigenesis and the precise manipulation of stem cell behaviors needed to be surmounted (<xref rid="B70" ref-type="bibr">70</xref>). Gene therapy differs from a glucocentric approach, utilizes lentivirus, adenovirus, adeno-associated virus (AAV), along with non-viral techniques like liposomes and naked DNA, to deliver the insulin gene to target tissues, such as CRISPR-Cas9 sequencing enables to precise modification mtDNA mutations associated with T2DM, offering potential therapeutic precision and safety for metabolic disorders (<xref rid="B72" ref-type="bibr">72</xref>, <xref rid="B73" ref-type="bibr">73</xref>).</p><p>Omic-related fields have illuminated a path of immense promise and significant potential for revolutionizing modern therapeutic interventions. Insist hyperglycemia impacts the metabolism of glucose, lipids, amino acids, as well as gut microbiota, which all in turn impact the drug responses of individuals living with T2DM.Hence, metabolomics, lipidomics and microbiomics are applied to uncover additional biomarkers that might better predict heterogeneity observed in personalized management outcome and enhance our understanding of disease mechanisms, thus offering new opportunities for various diabetic stages and patient-specific therapeutic interventions (<xref rid="B74" ref-type="bibr">74</xref>). Additionally, with the complex nature of T2DM and its widespread prevalence, the integration of precision medicine into all-around care should consider a myriad of factors encompass social, demographics, phenotypic, biochemical, genetic aspects, and individual patient variability (<xref rid="B75" ref-type="bibr">75</xref>). Complementary and alternative medicine (CAM) therapies herbal remedies like cinnamon, fenugreek, and bitter melon, allied with mindbody therapies, including yoga, tai chi, and meditation offers holistic and patient-centered approach to alleviate disease progression, have been viewed as complementary strategy to advance T2DM care (<xref rid="B2" ref-type="bibr">2</xref>).Moreover, interdisciplinary research is the foreword trend to develop diabetic treatment, artificial intelligence (AI) technologies analyze genes, proteins and metabolites, provide more intelligent and precise support from early screening, diagnosis to personalized treatment and monitoring, and leveraging machine learning algorithms to assess the risk trend in metabolic diseases and empower patients in self-management (<xref rid="B76" ref-type="bibr">76</xref>, <xref rid="B77" ref-type="bibr">77</xref>). While AI has opened new options for conquering complexity of the human insulin system, sole reliance on it for personalized treatment is far from enough, it still needs collaboration with healthcare professionals, researchers, and technical implementation experts to harness the full potential of AI in diabetic management (<xref rid="B78" ref-type="bibr">78</xref>).</p></sec></body><back><ack><title>Acknowledgments</title><p>We gratefully acknowledge the teachers of the Hospital of Chengdu University of Traditional Chinese Medicine for their strong support in this study, as well as the encouraging words given by the leaders of the hospital.</p></ack><sec sec-type="data-availability" id="s4"><title>Data availability statement</title><p>The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding authors.</p></sec><sec sec-type="author-contributions" id="s5"><title>Author contributions</title><p>LW: Writing &#x02013; original draft. LL: Resources, Writing &#x02013; review &#x00026; editing. JL: Methodology, Writing &#x02013; review &#x00026; editing. MY: Validation, Writing &#x02013; review &#x00026; editing. ZH: Writing &#x02013; review &#x00026; editing. CS: Writing &#x02013; review &#x00026; editing, Investigation. RY: Investigation, Writing &#x02013; review &#x00026; editing.</p></sec><sec sec-type="COI-statement" id="s7"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="disclaimer" id="s8"><title>Publisher&#x02019;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Caturano</surname><given-names>A</given-names></name><name><surname>D&#x02019;Angelo</surname><given-names>M</given-names></name><name><surname>Mormone</surname><given-names>A</given-names></name><name><surname>Russo</surname><given-names>V</given-names></name><name><surname>Mollica</surname><given-names>MP</given-names></name><name><surname>Salvatore</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Oxidative stress in type 2 diabetes: impacts from pathogenesis to lifestyle modifications</article-title>. <source>Curr Issues Mol Biol</source>. (<year>2023</year>) <volume>45</volume>:<page-range>6651&#x02013;66</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/cimb45080420</pub-id>
</mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McBenedict</surname><given-names>B</given-names></name><name><surname>Orfao</surname><given-names>AL</given-names></name><name><surname>Goh</surname><given-names>KS</given-names></name><name><surname>Yau</surname><given-names>RCC</given-names></name><name><surname>Alphonse</surname><given-names>B</given-names></name><name><surname>Machado Lima</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>The role of alternative medicine in managing type 2 diabetes: A comprehensive review</article-title>. <source>Cureus</source>. (<year>2024</year>) <volume>16</volume>:<elocation-id>e61965</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.7759/cureus.61965</pub-id>
<pub-id pub-id-type="pmid">38978922</pub-id>
</mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cannon</surname><given-names>A</given-names></name><name><surname>Handelsman</surname><given-names>Y</given-names></name><name><surname>Heile</surname><given-names>M</given-names></name><name><surname>Shannon</surname><given-names>M</given-names></name></person-group>. <article-title>Burden of illness in type 2 diabetes mellitus</article-title>. <source>J Manag Care Spec Pharm</source>. (<year>2018</year>) <volume>24</volume>:<fpage>S5</fpage>&#x02013;<lpage>S13</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.18553/jmcp.2018.24.9-a.s5</pub-id>
<pub-id pub-id-type="pmid">30156443</pub-id>
</mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Marx</surname><given-names>N</given-names></name><name><surname>Federici</surname><given-names>M</given-names></name><name><surname>Sch&#x000fc;tt</surname><given-names>K</given-names></name><name><surname>M&#x000fc;ller-Wieland</surname><given-names>D</given-names></name><name><surname>Ajjan</surname><given-names>RA</given-names></name><name><surname>Antunes</surname><given-names>MJ</given-names></name><etal/></person-group>. <article-title>2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes</article-title>. <source>Eur Heart J</source>. (<year>2023</year>) <volume>44</volume>:<page-range>4043&#x02013;140</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1093/eurheartj/ehad192</pub-id>
</mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Caturano</surname><given-names>A</given-names></name><name><surname>Galiero</surname><given-names>R</given-names></name><name><surname>Rocco</surname><given-names>M</given-names></name><name><surname>Tagliaferri</surname><given-names>G</given-names></name><name><surname>Piacevole</surname><given-names>A</given-names></name><name><surname>Nilo</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Modern challenges in type 2 diabetes: balancing new medications with multifactorial care</article-title>. <source>Biomedicines</source>. (<year>2024</year>) <volume>12</volume>:<elocation-id>2039</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/biomedicines12092039</pub-id>
<pub-id pub-id-type="pmid">39335551</pub-id>
</mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vicente</surname><given-names>AM</given-names></name><name><surname>Ballensiefen</surname><given-names>W</given-names></name><name><surname>J&#x000f6;nsson</surname><given-names>JI</given-names></name></person-group>. <article-title>How personalised medicine will transform healthcare by 2030: the ICPerMed vision</article-title>. <source>J Transl Med</source>. (<year>2020</year>) <volume>18</volume>:<fpage>180</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/s12967-020-02316-w</pub-id>
<pub-id pub-id-type="pmid">32345312</pub-id>
</mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Anderson</surname><given-names>S</given-names></name><name><surname>Bankier</surname><given-names>AT</given-names></name><name><surname>Barrell</surname><given-names>BG</given-names></name><name><surname>de Bruijn</surname><given-names>MH</given-names></name><name><surname>Coulson</surname><given-names>AR</given-names></name><name><surname>Drouin</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Sequence and organization of the human mitochondrial genome</article-title>. <source>Nature</source>. (<year>1981</year>) <volume>290</volume>:<page-range>457&#x02013;65</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/290457a0</pub-id>
</mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nolfi-Donegan</surname><given-names>D</given-names></name><name><surname>Braganza</surname><given-names>A</given-names></name><name><surname>Shiva</surname><given-names>S</given-names></name></person-group>. <article-title>Mitochondrial electron transport chain: Oxidative phosphorylation, oxidant production, and methods of measurement</article-title>. <source>Redox Biol</source>. (<year>2020</year>) <volume>37</volume>:<elocation-id>101674</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.redox.2020.101674</pub-id>
<pub-id pub-id-type="pmid">32811789</pub-id>
</mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Luo</surname><given-names>JS</given-names></name><name><surname>Ning</surname><given-names>JQ</given-names></name><name><surname>Chen</surname><given-names>ZY</given-names></name><name><surname>Li</surname><given-names>WJ</given-names></name><name><surname>Zhou</surname><given-names>RL</given-names></name><name><surname>Yan</surname><given-names>RY</given-names></name><etal/></person-group>. <article-title>The role of mitochondrial quality control in cognitive dysfunction in diabetes</article-title>. <source>Neurochem Res</source>. (<year>2022</year>) <volume>47</volume>:<page-range>2158&#x02013;72</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s11064-022-03631-y</pub-id>
</mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Martinez</surname><given-names>J</given-names></name><name><surname>Marmisolle</surname><given-names>I</given-names></name><name><surname>Tarallo</surname><given-names>D</given-names></name><name><surname>Quijano</surname><given-names>C</given-names></name></person-group>. <article-title>Mitochondrial bioenergetics and dynamics in secretion processes</article-title>. <source>Front Endocrinol</source>. (<year>2020</year>) <volume>11</volume>:<elocation-id>319</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fendo.2020.00319</pub-id>
</mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Thubron</surname><given-names>EB</given-names></name><name><surname>Rosa</surname><given-names>HS</given-names></name><name><surname>Hodges</surname><given-names>A</given-names></name><name><surname>Sivaprasad</surname><given-names>S</given-names></name><name><surname>Francis</surname><given-names>PT</given-names></name><name><surname>Pienaar</surname><given-names>IS</given-names></name><etal/></person-group>. <article-title>Regional mitochondrial DNA and cell-type changes in post-mortem brains of non-diabetic Alzheimer&#x02019;s disease are not present in diabetic Alzheimer&#x02019;s disease</article-title>. <source>Sci Rep</source>. (<year>2019</year>) <volume>9</volume>:<fpage>11386</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41598-019-47783-4</pub-id>
<pub-id pub-id-type="pmid">31388037</pub-id>
</mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Han</surname><given-names>W</given-names></name><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Adapentpronitrile, a new dipeptidyl peptidase-IV inhibitor, ameliorates diabetic neuronal injury through inhibiting mitochondria-related oxidative stress and apoptosis</article-title>. <source>Front Cell Neurosci</source>. (<year>2018</year>) <volume>12</volume>:<elocation-id>214</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fncel</pub-id>
<pub-id pub-id-type="pmid">30072873</pub-id>
</mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ipsen</surname><given-names>E&#x000d8;</given-names></name><name><surname>Madsen</surname><given-names>KS</given-names></name><name><surname>Chi</surname><given-names>Y</given-names></name><name><surname>Pedersen-Bjergaard</surname><given-names>U</given-names></name><name><surname>Richter</surname><given-names>B</given-names></name><name><surname>Metzendorf</surname><given-names>MI</given-names></name><etal/></person-group>. <article-title>Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus</article-title>. <source>Cochrane Database Syst Rev</source>. (<year>2020</year>) <volume>11</volume>:<elocation-id>CD013516</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1002/14651858.CD013516.pub2</pub-id>
<pub-id pub-id-type="pmid">33210751</pub-id>
</mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hallakou-Bozec</surname><given-names>S</given-names></name><name><surname>Vial</surname><given-names>G</given-names></name><name><surname>Kergoat</surname><given-names>M</given-names></name><name><surname>Fouqueray</surname><given-names>P</given-names></name><name><surname>Bolze</surname><given-names>S</given-names></name><name><surname>Borel</surname><given-names>AL</given-names></name><etal/></person-group>. <article-title>Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes</article-title>. <source>Diabetes Obes Metab</source>. (<year>2021</year>) <volume>23</volume>:<page-range>664&#x02013;73</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1111/dom</pub-id>
</mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Detaille</surname><given-names>D</given-names></name><name><surname>Vial</surname><given-names>G</given-names></name><name><surname>Borel</surname><given-names>AL</given-names></name><name><surname>Cottet-Rouselle</surname><given-names>C</given-names></name><name><surname>Hallakou-Bozec</surname><given-names>S</given-names></name><name><surname>Bolze</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Imeglimin prevents human endothelial cell death by inhibiting mitochondrial permeability transition without inhibiting mitochondrial respiration</article-title>. <source>Cell Death Discov</source>. (<year>2016</year>) <volume>2</volume>:<fpage>15072</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/cddiscovery.2015.72</pub-id>
<pub-id pub-id-type="pmid">27551496</pub-id>
</mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sultana</surname><given-names>MA</given-names></name><name><surname>Hia</surname><given-names>RA</given-names></name><name><surname>Akinsiku</surname><given-names>O</given-names></name><name><surname>Hegde</surname><given-names>V</given-names></name></person-group>. <article-title>Peripheral mitochondrial dysfunction: A potential contributor to the development of metabolic disorders and alzheimer&#x02019;s disease</article-title>. <source>Biol (Basel)</source>. (<year>2023</year>) <volume>12</volume>:<elocation-id>1019</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/biology12071019</pub-id>
</mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rius-P&#x000e9;rez</surname><given-names>S</given-names></name><name><surname>Torres-Cuevas</surname><given-names>I</given-names></name><name><surname>Mill&#x000e1;n</surname><given-names>I</given-names></name><name><surname>Ortega</surname><given-names>&#x000c1;L</given-names></name><name><surname>P&#x000e9;rez</surname><given-names>S</given-names></name></person-group>. <article-title>PGC-1<italic>&#x003b1;</italic>, inflammation, and oxidative stress: an integrative view in metabolism</article-title>. <source>Oxid Med Cell Longev</source>. (<year>2020</year>) <volume>2020</volume>:<elocation-id>1452696</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1155/2020/1452696</pub-id>
<pub-id pub-id-type="pmid">32215168</pub-id>
</mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tang</surname><given-names>BL</given-names></name></person-group>. <article-title>Sirt1 and the mitochondria</article-title>. <source>Mol Cells</source>. (<year>2016</year>) <volume>39</volume>:<fpage>87</fpage>&#x02013;<lpage>95</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.14348/molcells.2016.2318</pub-id>
<pub-id pub-id-type="pmid">26831453</pub-id>
</mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Galicia-Garcia</surname><given-names>U</given-names></name><name><surname>Benito-Vicente</surname><given-names>A</given-names></name><name><surname>Jebari</surname><given-names>S</given-names></name><name><surname>Larrea-Sebal</surname><given-names>A</given-names></name><name><surname>Siddiqi</surname><given-names>H</given-names></name><name><surname>Uribe</surname><given-names>KB</given-names></name><etal/></person-group>. <article-title>Pathophysiology of type 2 diabetes mellitus</article-title>. <source>Int J Mol Sci</source>. (<year>2020</year>) <volume>21</volume>:<elocation-id>6275</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/ijms21176275</pub-id>
<pub-id pub-id-type="pmid">32872570</pub-id>
</mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Golubitzky</surname><given-names>A</given-names></name><name><surname>Dan</surname><given-names>P</given-names></name><name><surname>Weissman</surname><given-names>S</given-names></name><name><surname>Link</surname><given-names>G</given-names></name><name><surname>Wikstrom</surname><given-names>JD</given-names></name><name><surname>Saada</surname><given-names>A</given-names></name></person-group>. <article-title>Screening for active small molecules in mitochondrial complex I deficient patient&#x02019;s fibroblasts, reveals AICAR as the most beneficial compound</article-title>. <source>PloS One</source>. (<year>2011</year>) <volume>6</volume>:<elocation-id>e26883</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1371/journal.pone.0026883</pub-id>
<pub-id pub-id-type="pmid">22046392</pub-id>
</mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Russell</surname><given-names>OM</given-names></name><name><surname>Gorman</surname><given-names>GS</given-names></name><name><surname>Lightowlers</surname><given-names>RN</given-names></name><name><surname>Turnbull</surname><given-names>DM</given-names></name></person-group>. <article-title>Mitochondrial diseases: hope for the future</article-title>. <source>Cell</source>. (<year>2020</year>) <volume>181</volume>:<page-range>168&#x02013;88</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.cell.2020.02.051</pub-id>
</mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sz&#x00171;cs</surname><given-names>G</given-names></name><name><surname>Pipicz</surname><given-names>M</given-names></name><name><surname>Szab&#x000f3;</surname><given-names>MR</given-names></name><name><surname>Csont</surname><given-names>T</given-names></name><name><surname>T&#x000f6;r&#x000f6;k</surname><given-names>L</given-names></name><name><surname>Csonka</surname><given-names>C</given-names></name></person-group>. <article-title>Effect of eccentric exercise on metabolic health in diabetes and obesity</article-title>. <source>Sports Med Open</source>. (<year>2023</year>) <volume>9</volume>:<fpage>91</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/s40798-023-00596-2</pub-id>
<pub-id pub-id-type="pmid">37775653</pub-id>
</mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nussbaumerova</surname><given-names>B</given-names></name><name><surname>Rosolova</surname><given-names>H</given-names></name></person-group>. <article-title>Obesity and dyslipidemia</article-title>. <source>Curr Atheroscler Rep</source>. (<year>2023</year>) <volume>25</volume>:<page-range>947&#x02013;55</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s11883-023-01167-2</pub-id>
</mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xu</surname><given-names>JQ</given-names></name><name><surname>Jiang</surname><given-names>MX</given-names></name><name><surname>Xu</surname><given-names>YJ</given-names></name><name><surname>Dong</surname><given-names>SJ</given-names></name></person-group>. <article-title>Research progress in the regulation of functional homeostasis of adipose tissue by exosomal miRNA</article-title>. <source>Sheng Li Xue Bao</source>. (<year>2024</year>) <volume>76</volume>:<fpage>791</fpage>&#x02013;<lpage>800</lpage>.<pub-id pub-id-type="pmid">39468815</pub-id>
</mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wankhade</surname><given-names>UD</given-names></name><name><surname>Shen</surname><given-names>M</given-names></name><name><surname>Yadav</surname><given-names>H</given-names></name><name><surname>Thakali</surname><given-names>KM</given-names></name></person-group>. <article-title>Novel browning agents, mechanisms, and therapeutic potentials of brown adipose tissue</article-title>. <source>BioMed Res Int</source>. (<year>2016</year>) <volume>2016</volume>:<fpage>2365609</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1155/2016/2365609</pub-id>
<pub-id pub-id-type="pmid">28105413</pub-id>
</mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ghesmati</surname><given-names>Z</given-names></name><name><surname>Rashid</surname><given-names>M</given-names></name><name><surname>Fayezi</surname><given-names>S</given-names></name><name><surname>Gieseler</surname><given-names>F</given-names></name><name><surname>Alizadeh</surname><given-names>E</given-names></name><name><surname>Darabi</surname><given-names>M</given-names></name></person-group>. <article-title>An update on the secretory functions of brown, white, and beige adipose tissue: Towards therapeutic applications</article-title>. <source>Rev Endocr Metab Disord</source>. (<year>2024</year>) <volume>25</volume>:<fpage>279</fpage>&#x02013;<lpage>308</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s11154-023-09850-0</pub-id>
<pub-id pub-id-type="pmid">38051471</pub-id>
</mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>de Mara&#x000f1;&#x000f3;n</surname><given-names>AM</given-names></name><name><surname>D&#x000ed;az-Pozo</surname><given-names>P</given-names></name><name><surname>Canet</surname><given-names>F</given-names></name><name><surname>D&#x000ed;az-Morales</surname><given-names>N</given-names></name><name><surname>Abad-Jim&#x000e9;nez</surname><given-names>Z</given-names></name><name><surname>L&#x000f3;pez-Dom&#x000e8;nech</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Metformin modulates mitochondrial function and mitophagy in peripheral blood mononuclear cells from type 2 diabetic patients</article-title>. <source>Redox Biol</source>. (<year>2022</year>) <volume>53</volume>:<elocation-id>102342</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.redox.2022.102342</pub-id>
<pub-id pub-id-type="pmid">35605453</pub-id>
</mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fatima</surname><given-names>A</given-names></name><name><surname>Rasool</surname><given-names>S</given-names></name><name><surname>Devi</surname><given-names>S</given-names></name><name><surname>Talha</surname><given-names>M</given-names></name><name><surname>Waqar</surname><given-names>F</given-names></name><name><surname>Nasir</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Exploring the cardiovascular benefits of sodium-glucose cotransporter-2 (SGLT2) inhibitors: expanding horizons beyond diabetes management</article-title>. <source>Cureus</source>. (<year>2023</year>) <volume>15</volume>:<elocation-id>e46243</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.7759/cureus.46243</pub-id>
<pub-id pub-id-type="pmid">37908957</pub-id>
</mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tomita</surname><given-names>I</given-names></name><name><surname>Kume</surname><given-names>S</given-names></name><name><surname>Sugahara</surname><given-names>S</given-names></name><name><surname>Osawa</surname><given-names>N</given-names></name><name><surname>Yamahara</surname><given-names>K</given-names></name><name><surname>Yasuda-Yamahara</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>SGLT2 inhibition mediates protection from diabetic kidney disease by promoting ketone body-induced mTORC1 inhibition</article-title>. <source>Cell Metab</source>. (<year>2020</year>) <volume>32</volume>:<fpage>404</fpage>&#x02013;<lpage>419.e6</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.cmet.2020.06.020</pub-id>
<pub-id pub-id-type="pmid">32726607</pub-id>
</mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cai</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Gao</surname><given-names>X</given-names></name></person-group>. <article-title>The association between the dosage of SGLT2 inhibitor and weight reduction in type 2 diabetes patients: A meta-analysis</article-title>. <source>Obesity</source>. (<year>2018</year>) <volume>26</volume>:<fpage>70</fpage>&#x02013;<lpage>80</lpage>:<elocation-id>et al</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1002/oby.22066</pub-id>
<pub-id pub-id-type="pmid">29165885</pub-id>
</mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Thomas</surname><given-names>MK</given-names></name><name><surname>Nikooienejad</surname><given-names>A</given-names></name><name><surname>Bray</surname><given-names>R</given-names></name><name><surname>Cui</surname><given-names>X</given-names></name><name><surname>Wilson</surname><given-names>J</given-names></name><name><surname>Duffin</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes</article-title>. <source>J Clin Endocrinol Metab</source>. (<year>2021</year>) <volume>106</volume>:<page-range>388&#x02013;96</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1210/clinem/dgaa863</pub-id>
</mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zimmermann</surname><given-names>T</given-names></name><name><surname>Thomas</surname><given-names>L</given-names></name><name><surname>Baader-Pagler</surname><given-names>T</given-names></name><name><surname>Haebel</surname><given-names>P</given-names></name><name><surname>Simon</surname><given-names>E</given-names></name><name><surname>Reindl</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy</article-title>. <source>Mol Metab</source>. (<year>2022</year>) <volume>66</volume>:<elocation-id>101633</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.molmet.2022.101633</pub-id>
<pub-id pub-id-type="pmid">36356832</pub-id>
</mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kermansaravi</surname><given-names>M</given-names></name><name><surname>Chiappetta</surname><given-names>S</given-names></name><name><surname>Kassir</surname><given-names>R</given-names></name><name><surname>Bosco</surname><given-names>A</given-names></name><name><surname>Giudicelli</surname><given-names>X</given-names></name><name><surname>Lainas</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Efficacy of one anastomosis gastric bypass versus sleeve gastrectomy and roux-en-Y gastric bypass for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis of randomized clinical trials</article-title>. <source>Obes Surg</source>. (<year>2024</year>) <volume>34</volume>:<page-range>4555&#x02013;62</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s11695-024-07564-z</pub-id>
</mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Tang</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Ma</surname><given-names>X</given-names></name><name><surname>Schnabl</surname><given-names>B</given-names></name><name><surname>Tilg</surname><given-names>H</given-names></name></person-group>. <article-title>Gut microbiome, liver immunology, and liver diseases</article-title>. <source>Cell Mol Immunol</source>. (<year>2021</year>) <volume>18</volume>:<fpage>4</fpage>&#x02013;<lpage>17</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41423-020-00592-6</pub-id>
<pub-id pub-id-type="pmid">33318628</pub-id>
</mixed-citation></ref><ref id="B35"><label>35</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Z</given-names></name><name><surname>Sun</surname><given-names>B</given-names></name><name><surname>Yu</surname><given-names>D</given-names></name><name><surname>Zhu</surname><given-names>C</given-names></name></person-group>. <article-title>Gut microbiota: an important player in type 2 diabetes mellitus</article-title>. <source>Front Cell Infect Microbiol</source>. (<year>2022</year>) <volume>12</volume>:<elocation-id>834485</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fcimb.2022.834485</pub-id>
<pub-id pub-id-type="pmid">35242721</pub-id>
</mixed-citation></ref><ref id="B36"><label>36</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mercer</surname><given-names>K</given-names></name><name><surname>Yeruva</surname><given-names>L</given-names></name><name><surname>Pack</surname><given-names>L</given-names></name><name><surname>Graham</surname><given-names>JL</given-names></name><name><surname>Stanhope</surname><given-names>KL</given-names></name><name><surname>Chintapalli</surname><given-names>SV</given-names></name><etal/></person-group>. <article-title>Xenometabolite signatures in the UC davis type 2 diabetes mellitus rat model revealed using a metabolomics platform enriched with microbe-derived metabolites. American journal of physiology</article-title>. <source>Gastrointest. Liver. Physiol</source>. (<year>2020</year>) <volume>319</volume>:<page-range>G157&#x02013;69</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1152/ajpgi.00105.2020</pub-id>
</mixed-citation></ref><ref id="B37"><label>37</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Noureldein</surname><given-names>M</given-names></name><name><surname>Bitar</surname><given-names>S</given-names></name><name><surname>Youssef</surname><given-names>N</given-names></name><name><surname>Azar</surname><given-names>S</given-names></name><name><surname>Eid</surname><given-names>AA</given-names></name></person-group>. <article-title>Butyrate modulates diabetes-linked gut dysbiosis: epigenetic and mechanistic modifications</article-title>. <source>J Mol Endocrinol</source>. (<year>2020</year>) <volume>64</volume>:<fpage>29</fpage>&#x02013;<lpage>42</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1530/jme-19-0132</pub-id>
<pub-id pub-id-type="pmid">31770101</pub-id>
</mixed-citation></ref><ref id="B38"><label>38</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>JY</given-names></name><name><surname>Lee</surname><given-names>YS</given-names></name><name><surname>Kim</surname><given-names>Y</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Ryu</surname><given-names>S</given-names></name><name><surname>Fukuda</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Gut commensal Bacteroides acidifaciens prevents obesity and improves insulin sensitivity in mice</article-title>. <source>Mucosal Immunol</source>. (<year>2017</year>) <volume>10</volume>:<page-range>104&#x02013;16</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/mi.2016.42</pub-id>
</mixed-citation></ref><ref id="B39"><label>39</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Shen</surname><given-names>D</given-names></name><name><surname>Fang</surname><given-names>Z</given-names></name><name><surname>Jie</surname><given-names>Z</given-names></name><name><surname>Qiu</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Human gut microbiota changes reveal the progression of glucose intolerance</article-title>. <source>PloS One</source>. (<year>2013</year>) <volume>8</volume>:<elocation-id>e71108</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1371/journal.pone.0071108</pub-id>
<pub-id pub-id-type="pmid">24013136</pub-id>
</mixed-citation></ref><ref id="B40"><label>40</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hamamah</surname><given-names>S</given-names></name><name><surname>Covasa</surname><given-names>M</given-names></name></person-group>. <article-title>Harnessing prebiotics to improve type 2 diabetes outcomes</article-title>. <source>Nutrients</source>. (<year>2024</year>) <volume>16</volume>:<elocation-id>3447</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/nu16203447</pub-id>
<pub-id pub-id-type="pmid">39458444</pub-id>
</mixed-citation></ref><ref id="B41"><label>41</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jeyaraman</surname><given-names>M</given-names></name><name><surname>Mariappan</surname><given-names>T</given-names></name><name><surname>Jeyaraman</surname><given-names>N</given-names></name><name><surname>Muthu</surname><given-names>S</given-names></name><name><surname>Ramasubramanian</surname><given-names>S</given-names></name><name><surname>Santos</surname><given-names>GS</given-names></name><etal/></person-group>. <article-title>Gut microbiome: A revolution in type II diabetes mellitus</article-title>. <source>World J Diabetes</source>. (<year>2024</year>) <volume>15</volume>:<page-range>1874&#x02013;88</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.4239/wjd.v15.i9.1874</pub-id>
</mixed-citation></ref><ref id="B42"><label>42</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vanweert</surname><given-names>F</given-names></name><name><surname>de Ligt</surname><given-names>M</given-names></name><name><surname>Hoeks</surname><given-names>J</given-names></name><name><surname>Hesselink</surname><given-names>MKC</given-names></name><name><surname>Schrauwen</surname><given-names>P</given-names></name><name><surname>Phielix</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Elevated plasma branched-chain amino acid levels correlate with type 2 diabetes-related metabolic disturbances</article-title>. <source>J Clin Endocrinol Metab</source>. (<year>2021</year>) <volume>106</volume>:<page-range>e1827&#x02013;1836</page-range>:<elocation-id>et al</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1210/clinem/dgaa751</pub-id>
</mixed-citation></ref><ref id="B43"><label>43</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Sun</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Branched-chain amino acids exacerbate obesity-related hepatic glucose and lipid metabolic disorders via attenuating akt2 signaling</article-title>. <source>Diabetes</source>. (<year>2020</year>) <volume>69</volume>:<page-range>1164&#x02013;77</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.2337/db19-0920</pub-id>
</mixed-citation></ref><ref id="B44"><label>44</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Shi</surname><given-names>H</given-names></name><name><surname>Wei</surname><given-names>W</given-names></name><name><surname>Shang</surname><given-names>J</given-names></name><name><surname>Zheng</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Characteristics of the gut microbiota and metabolism in patients with latent autoimmune diabetes in adults: A case-control study</article-title>. <source>Diabetes Care</source>. (<year>2021</year>) <volume>44</volume>:<page-range>2738&#x02013;46</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.2337/dc20-2975</pub-id>
</mixed-citation></ref><ref id="B45"><label>45</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rittiphairoj</surname><given-names>T</given-names></name><name><surname>Pongpirul</surname><given-names>K</given-names></name><name><surname>Janchot</surname><given-names>K</given-names></name><name><surname>Mueller</surname><given-names>NT</given-names></name><name><surname>Li</surname><given-names>T</given-names></name></person-group>. <article-title>Probiotics contribute to glycemic control in patients with type 2 diabetes mellitus: a systematic review and meta-analysis</article-title>. <source>Adv Nutr</source>. (<year>2021</year>) <volume>12</volume>:<page-range>722&#x02013;34</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1093/advances/nmaa133</pub-id>
</mixed-citation></ref><ref id="B46"><label>46</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Fang</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Xia</surname><given-names>H</given-names></name><name><surname>Jie</surname><given-names>Z</given-names></name><name><surname>Han</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Effects of acarbose on the gut microbiota of prediabetic patients: A randomized, double-blind, controlled crossover trial</article-title>. <source>Diabetes Ther</source>. (<year>2017</year>) <volume>8</volume>:<fpage>293</fpage>&#x02013;<lpage>307</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s13300-017-0226-y</pub-id>
<pub-id pub-id-type="pmid">28130771</pub-id>
</mixed-citation></ref><ref id="B47"><label>47</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Xiao</surname><given-names>X</given-names></name><name><surname>Zheng</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Yu</surname><given-names>M</given-names></name><name><surname>Ping</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Featured article: Structure moderation of gut microbiota in liraglutide-treated diabetic male rats</article-title>. <source>Exp Biol Med</source>. (<year>2018</year>) <volume>243</volume>:<fpage>34</fpage>&#x02013;<lpage>44</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1177/1535370217743765</pub-id>
</mixed-citation></ref><ref id="B48"><label>48</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cefalo</surname><given-names>CMA</given-names></name><name><surname>Cinti</surname><given-names>F</given-names></name><name><surname>Moffa</surname><given-names>S</given-names></name><name><surname>Impronta</surname><given-names>F</given-names></name><name><surname>Sorice</surname><given-names>GP</given-names></name><name><surname>Mezza</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives</article-title>. <source>Cardiovasc Diabetol</source>. (<year>2019</year>) <volume>18</volume>:<fpage>20</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/s12933-019-0828-y</pub-id>
<pub-id pub-id-type="pmid">30819210</pub-id>
</mixed-citation></ref><ref id="B49"><label>49</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Eisenberg</surname><given-names>T</given-names></name><name><surname>Knauer</surname><given-names>H</given-names></name><name><surname>Schauer</surname><given-names>A</given-names></name><name><surname>B&#x000fc;ttner</surname><given-names>S</given-names></name><name><surname>Ruckenstuhl</surname><given-names>C</given-names></name><name><surname>Carmona-Gutierrez</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Induction of autophagy by spermidine promotes longevity</article-title>. <source>Nat Cell Biol</source>. (<year>2009</year>) <volume>11</volume>:<page-range>1305&#x02013;14</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/ncb1975</pub-id>
</mixed-citation></ref><ref id="B50"><label>50</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cheng</surname><given-names>S</given-names></name><name><surname>Ma</surname><given-names>X</given-names></name><name><surname>Geng</surname><given-names>S</given-names></name><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Fecal microbiota transplantation beneficially regulates intestinal mucosal autophagy and alleviates gut barrier injury</article-title>. <source>mSystems</source>. (<year>2018</year>) <volume>3</volume>:<page-range>e00137&#x02013;18</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1128/mSystems.00137-18</pub-id>
</mixed-citation></ref><ref id="B51"><label>51</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Arabshomali</surname><given-names>A</given-names></name><name><surname>Bazzazzadehgan</surname><given-names>S</given-names></name><name><surname>Mahdi</surname><given-names>F</given-names></name><name><surname>Shariat-Madar</surname><given-names>Z</given-names></name></person-group>. <article-title>Potential benefits of antioxidant phytochemicals in type 2 diabetes</article-title>. <source>Molecules</source>. (<year>2023</year>) <volume>28</volume>:<elocation-id>7209</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/molecules28207209</pub-id>
<pub-id pub-id-type="pmid">37894687</pub-id>
</mixed-citation></ref><ref id="B52"><label>52</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tangvarasittichai</surname><given-names>S</given-names></name></person-group>. <article-title>Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus</article-title>. <source>World J Diabetes</source>. (<year>2015</year>) <volume>6</volume>:<page-range>456&#x02013;80</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.4239/wjd.v6.i3.456</pub-id>
</mixed-citation></ref><ref id="B53"><label>53</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gao</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name></person-group>. <article-title>Fatty acid &#x003b2;-oxidation in kidney diseases: perspectives on pathophysiological mechanisms and therapeutic opportunities</article-title>. <source>Front.Pharmacol</source>. (<year>2022</year>) <volume>13</volume>:<elocation-id>805281</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fphar.2022.805281</pub-id>
<pub-id pub-id-type="pmid">35517820</pub-id>
</mixed-citation></ref><ref id="B54"><label>54</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pawlak</surname><given-names>M</given-names></name><name><surname>Lefebvre</surname><given-names>P</given-names></name><name><surname>Staels</surname><given-names>B</given-names></name></person-group>. <article-title>Molecular mechanism of PPAR&#x003b1; action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease</article-title>. <source>J Hepatol</source>. (<year>2015</year>) <volume>62</volume>:<page-range>720&#x02013;33</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.jhep.2014.10.039</pub-id>
</mixed-citation></ref><ref id="B55"><label>55</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ke</surname><given-names>R</given-names></name><name><surname>Xu</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Luo</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>D</given-names></name></person-group>. <article-title>Mechanisms of AMPK in the maintenance of AT balance during energy metabolism</article-title>. <source>Cell Biol Int</source>. (<year>2018</year>) <volume>42</volume>:<page-range>384&#x02013;92</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1002/cbin.10915</pub-id>
</mixed-citation></ref><ref id="B56"><label>56</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Iheagwam</surname><given-names>FN</given-names></name><name><surname>Batiha</surname><given-names>GE</given-names></name><name><surname>Ogunlana</surname><given-names>OO</given-names></name><name><surname>Chinedu</surname><given-names>SN</given-names></name></person-group>. <article-title>
<italic>Terminalia catappa</italic> extract palliates redox imbalance and inflammation in diabetic rats by upregulating nrf-2 gene</article-title>. <source>Int J Inflam</source>. (<year>2021</year>) <volume>2021</volume>:<elocation-id>9778486</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1155/2021/9778486</pub-id>
<pub-id pub-id-type="pmid">34956587</pub-id>
</mixed-citation></ref><ref id="B57"><label>57</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dakroub</surname><given-names>A</given-names></name><name><surname>Nasser S</surname><given-names>A</given-names></name><name><surname>Younis</surname><given-names>N</given-names></name><name><surname>Bhagani</surname><given-names>H</given-names></name><name><surname>Al-Dhaheri</surname><given-names>Y</given-names></name><name><surname>Pintus</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Visfatin: A possible role in cardiovasculo-metabolic disorders cells</article-title>. <source>Cells</source>. (<year>2020</year>) <volume>9</volume>:<fpage>2444</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/cells9112444</pub-id>
<pub-id pub-id-type="pmid">33182523</pub-id>
</mixed-citation></ref><ref id="B58"><label>58</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>S</surname><given-names>S</given-names></name><name><surname>Hegde</surname><given-names>SV</given-names></name><name><surname>Agarwal</surname><given-names>SV</given-names></name><name><surname>Ns</surname><given-names>D</given-names></name><name><surname>Pillai</surname><given-names>A</given-names></name><name><surname>Shah</surname><given-names>SN</given-names></name><etal/></person-group>. <article-title>Biomarkers of oxidative stress and their clinical relevance in type 2 diabetes mellitus patients: A systematic review</article-title>. <source>Cureus</source>. (<year>2024</year>) <volume>16</volume>:<elocation-id>e66570</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.7759/cureus.66570</pub-id>
<pub-id pub-id-type="pmid">39252730</pub-id>
</mixed-citation></ref><ref id="B59"><label>59</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Iheagwam</surname><given-names>FN</given-names></name><name><surname>Iheagwam</surname><given-names>OT</given-names></name><name><surname>Onuoha</surname><given-names>MK</given-names></name><name><surname>Ogunlana</surname><given-names>OO</given-names></name><name><surname>Chinedu</surname><given-names>SN</given-names></name></person-group>. <article-title>Terminalia catappa aqueous leaf extract reverses insulin resistance, improves glucose transport and activates PI3K/AKT signalling in high fat/streptozotocin-induced diabetic rats</article-title>. <source>Sci Rep</source>. (<year>2022</year>) <volume>12</volume>:<fpage>10711</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41598-022-15114-9</pub-id>
<pub-id pub-id-type="pmid">35739183</pub-id>
</mixed-citation></ref><ref id="B60"><label>60</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mason</surname><given-names>SA</given-names></name><name><surname>Wadley</surname><given-names>GD</given-names></name><name><surname>Keske</surname><given-names>MA</given-names></name><name><surname>Parker</surname><given-names>L</given-names></name></person-group>. <article-title>Effect of mitochondrial-targeted antioxidants on glycaemic control, cardiovascular health, and oxidative stress in humans: A systematic review and meta-analysis of randomized controlled trials</article-title>. <source>Diabetes Obes Metab</source>. (<year>2022</year>) <volume>24</volume>:<page-range>1047&#x02013;60</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1111/dom.14669</pub-id>
</mixed-citation></ref><ref id="B61"><label>61</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Veluthakal</surname><given-names>R</given-names></name><name><surname>Esparza</surname><given-names>D</given-names></name><name><surname>Hoolachan</surname><given-names>JM</given-names></name><name><surname>Balakrishnan</surname><given-names>R</given-names></name><name><surname>Ahn</surname><given-names>M</given-names></name><name><surname>Oh</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Mitochondrial dysfunction, oxidative stress, and inter-organ miscommunications in T2D progression</article-title>. <source>Int J Mol Sci</source>. (<year>2024</year>) <volume>25</volume>:<elocation-id>1504</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/ijms25031504</pub-id>
<pub-id pub-id-type="pmid">38338783</pub-id>
</mixed-citation></ref><ref id="B62"><label>62</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Karunakaran</surname><given-names>U</given-names></name><name><surname>Elumalai</surname><given-names>S</given-names></name><name><surname>Moon</surname><given-names>JS</given-names></name><name><surname>Won</surname><given-names>KC</given-names></name></person-group>. <article-title>Pioglitazoneinduced AMPK-glutaminase-1 prevents high glucose-induced pancreatic &#x003b2;-cell dysfunction by glutathione antioxidant system</article-title>. <source>Redox Biol</source>. (<year>2021</year>) <volume>45</volume>:<elocation-id>102029</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.redox.2021.102029</pub-id>
<pub-id pub-id-type="pmid">34107382</pub-id>
</mixed-citation></ref><ref id="B63"><label>63</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Moon</surname><given-names>JS</given-names></name><name><surname>Karunakaran</surname><given-names>U</given-names></name><name><surname>Elumalai</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>IK</given-names></name><name><surname>Lee</surname><given-names>HW</given-names></name><name><surname>Kim</surname><given-names>YW</given-names></name><etal/></person-group>. <article-title>Metformin prevents glucotoxicity by alleviating oxidative and ER stress-induced CD36 expression in pancreatic beta cells</article-title>. <source>J Diabetes Complications</source>. (<year>2017</year>) <volume>31</volume>:<fpage>21</fpage>&#x02013;<lpage>30</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.jdiacomp.2016.09.001</pub-id>
<pub-id pub-id-type="pmid">27662780</pub-id>
</mixed-citation></ref><ref id="B64"><label>64</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Caturano</surname><given-names>A</given-names></name><name><surname>Rocco</surname><given-names>M</given-names></name><name><surname>Tagliaferri</surname><given-names>G</given-names></name><name><surname>Piacevole</surname><given-names>A</given-names></name><name><surname>Nilo</surname><given-names>D</given-names></name><name><surname>Di Lorenzo</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Oxidative stress and cardiovascular complications in type 2 diabetes: from pathophysiology to lifestyle modifications</article-title>. <source>Antioxidants</source>. (<year>2025</year>) <volume>14</volume>:<elocation-id>72</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/antiox14010072</pub-id>
<pub-id pub-id-type="pmid">39857406</pub-id>
</mixed-citation></ref><ref id="B65"><label>65</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Abdul-Rahman</surname><given-names>T</given-names></name><name><surname>Roy</surname><given-names>P</given-names></name><name><surname>Ahmed</surname><given-names>FK</given-names></name><name><surname>Mueller-Gomez</surname><given-names>JL</given-names></name><name><surname>Sarkar</surname><given-names>S</given-names></name><name><surname>Garg</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>The power of three: Retatrutide&#x02019;s role in modern obesity and diabetes therapy</article-title>. <source>Eur J Pharmacol</source>. (<year>2024</year>) <volume>985</volume>:<elocation-id>177095</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.ejphar.2024.177095</pub-id>
<pub-id pub-id-type="pmid">39515565</pub-id>
</mixed-citation></ref><ref id="B66"><label>66</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sanyal</surname><given-names>AJ</given-names></name><name><surname>Kaplan</surname><given-names>LM</given-names></name><name><surname>Frias</surname><given-names>JP</given-names></name><name><surname>Brouwers</surname><given-names>B</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Thomas</surname><given-names>MK</given-names></name><etal/></person-group>. <article-title>Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial</article-title>. <source>Nat Med</source>. (<year>2024</year>) <volume>30</volume>:<page-range>2037&#x02013;48</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41591-024-03018-2</pub-id>
</mixed-citation></ref><ref id="B67"><label>67</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Caturano</surname><given-names>A</given-names></name><name><surname>Galiero</surname><given-names>R</given-names></name><name><surname>Loffredo</surname><given-names>G</given-names></name><name><surname>Vetrano</surname><given-names>E</given-names></name><name><surname>Medicamento</surname><given-names>G</given-names></name><name><surname>Acierno</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Effects of a combination of empagliflozin plus metformin vs. Metformin monotherapy on NAFLD progression in type 2 diabetes: the IMAGIN pilot study</article-title>. <source>Biomedicines</source>. (<year>2023</year>) <volume>11</volume>:<elocation-id>322</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/biomedicines11020322</pub-id>
<pub-id pub-id-type="pmid">36830859</pub-id>
</mixed-citation></ref><ref id="B68"><label>68</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Duan</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Xi</surname><given-names>S</given-names></name></person-group>. <article-title>Effects of a novel glucokinase activator, HMS5552, on glucose metabolism in a rat model of type 2 diabetes mellitus</article-title>. <source>J Diabetes Res</source>. (<year>2017</year>) <volume>2017</volume>:<elocation-id>5812607</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1155/2017/5812607</pub-id>
<pub-id pub-id-type="pmid">28191470</pub-id>
</mixed-citation></ref><ref id="B69"><label>69</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vella</surname><given-names>A</given-names></name><name><surname>Freeman</surname><given-names>JLR</given-names></name><name><surname>Dunn</surname><given-names>I</given-names></name><name><surname>Keller</surname><given-names>K</given-names></name><name><surname>Buse</surname><given-names>JB</given-names></name><name><surname>Valcarce</surname><given-names>C</given-names></name></person-group>. <article-title>Targeting hepatic glucokinase to treat diabetes with TTP399, a hepatoselective glucokinase activator</article-title>. <source>Sci Transl Med</source>. (<year>2019</year>) <volume>11</volume>:<elocation-id>eaau3441</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1126/scitranslmed.aau3441</pub-id>
<pub-id pub-id-type="pmid">30651321</pub-id>
</mixed-citation></ref><ref id="B70"><label>70</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Raoufinia</surname><given-names>R</given-names></name><name><surname>Rahimi</surname><given-names>HR</given-names></name><name><surname>Saburi</surname><given-names>E</given-names></name><name><surname>Moghbeli</surname><given-names>M</given-names></name></person-group>. <article-title>Advances and challenges of the cell-based therapies among diabetic patients</article-title>. <source>J Transl Med</source>. (<year>2024</year>) <volume>22</volume>:<fpage>435</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/s12967-024-05226-3</pub-id>
<pub-id pub-id-type="pmid">38720379</pub-id>
</mixed-citation></ref><ref id="B71"><label>71</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ma</surname><given-names>X</given-names></name><name><surname>Yao</surname><given-names>M</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Yue</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Functional immune cellderived exosomes engineered for the trilogy of radiotherapy sensitization</article-title>. <source>Adv Sci</source>. (<year>2022</year>) <volume>9</volume>:<elocation-id>e2106031</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1002/advs.202106031</pub-id>
</mixed-citation></ref><ref id="B72"><label>72</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kar</surname><given-names>B</given-names></name><name><surname>Castillo</surname><given-names>SR</given-names></name><name><surname>Sabharwal</surname><given-names>A</given-names></name><name><surname>Clark</surname><given-names>KJ</given-names></name><name><surname>Ekker</surname><given-names>SC</given-names></name></person-group>. <article-title>Mitochondrial base editing: recent advances towards therapeutic opportunities</article-title>. <source>Int J Mol Sci</source>. (<year>2023</year>) <volume>24</volume>:<elocation-id>5798</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/ijms24065798</pub-id>
<pub-id pub-id-type="pmid">36982871</pub-id>
</mixed-citation></ref><ref id="B73"><label>73</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wong</surname><given-names>MS</given-names></name><name><surname>Hawthorne</surname><given-names>WJ</given-names></name><name><surname>Manolios</surname><given-names>N</given-names></name></person-group>. <article-title>Gene therapy in diabetes</article-title>. <source>Self Nonself</source>. (<year>2010</year>) <volume>1</volume>:<fpage>165</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.4161/self.1.3.12643</pub-id>
<pub-id pub-id-type="pmid">21487475</pub-id>
</mixed-citation></ref><ref id="B74"><label>74</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rakusanova</surname><given-names>S</given-names></name><name><surname>Cajka</surname><given-names>T</given-names></name></person-group>. <article-title>Metabolomics and lipidomics for studying metabolic syndrome: insights into cardiovascular diseases, type 1 &#x00026; 2 diabetes, and metabolic dysfunction-associated steatotic liver disease</article-title>. <source>Physiol Res</source>. (<year>2024</year>) <volume>73</volume>:<page-range>S165&#x02013;83</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.33549/physiolres.935443</pub-id>
</mixed-citation></ref><ref id="B75"><label>75</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Oh</surname><given-names>SH</given-names></name><name><surname>Lee</surname><given-names>SJ</given-names></name><name><surname>Park</surname><given-names>J</given-names></name></person-group>. <article-title>Precision medicine for hypertension patients with type 2 diabetes via reinforcement learning</article-title>. <source>J Pers Med</source>. (<year>2022</year>) <volume>12</volume>:<elocation-id>87</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/jpm12010087</pub-id>
<pub-id pub-id-type="pmid">35055402</pub-id>
</mixed-citation></ref><ref id="B76"><label>76</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hsu</surname><given-names>NW</given-names></name><name><surname>Chou</surname><given-names>KC</given-names></name><name><surname>Wang</surname><given-names>YT</given-names></name><name><surname>Hung</surname><given-names>CL</given-names></name><name><surname>Kuo</surname><given-names>CF</given-names></name><name><surname>Tsai</surname><given-names>SY</given-names></name></person-group>. <article-title>Building a model for predicting metabolic syndrome using artificial intelligence based on an investigation of whole-genome sequencing</article-title>. <source>J Transl Med</source>. (<year>2022</year>) <volume>20</volume>:<fpage>190</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/s12967-022-03379-7</pub-id>
<pub-id pub-id-type="pmid">35484552</pub-id>
</mixed-citation></ref><ref id="B77"><label>77</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Maiese</surname><given-names>K</given-names></name></person-group>. <article-title>Diabetes mellitus and glymphatic dysfunction: Roles for oxidative stress, mitochondria, circadian rhythm, artificial intelligence, and imaging</article-title>. <source>World J Diabetes</source>. (<year>2025</year>) <volume>16</volume>:<elocation-id>98948</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.4239/wjd.v16.i1.98948</pub-id>
<pub-id pub-id-type="pmid">39817214</pub-id>
</mixed-citation></ref><ref id="B78"><label>78</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tahir</surname><given-names>F</given-names></name><name><surname>Farhan</surname><given-names>M</given-names></name></person-group>. <article-title>Exploring the progress of artificial intelligence in managing type 2 diabetes mellitus: a comprehensive review of present innovations and anticipated challenges ahead</article-title>. <source>Front Clin Diabetes Healthc</source>. (<year>2023</year>) <volume>4</volume>:<elocation-id>1316111</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fcdhc.2023.1316111</pub-id>
<pub-id pub-id-type="pmid">38161783</pub-id>
</mixed-citation></ref></ref-list></back></article>